Focus on Cell Therapy Gene Therapy AstraZeneca continues to seek new cooperation opportunities in China

On September 27 and 28,"2024 AstraZeneca China R & D Day-Reshaping Patient's Life Trajectory "Chronic DiseasesAnd rare disease events were successfully held in Shanghai.
This research and development day focused on hot topics of cell therapy and gene therapy, high incidence of hypertension, kidney, infectious diseases, bronchial diseases and other fields in China. During the two-day period,One keynote forum and eight sub-forums. In terms of influence and topic depth, it has been upgraded again, with big coffee gathering, hot spots and dry goods full.
From Chinese research institutes, clinical research centers, multinational enterprises, local innovative enterprises, overseas universities.50 top experts, scholars and enterprise leaders at home and abroadIn person, with nearly 20 relevant AstraZeneca global R & D team leaders also participated in the R & D day,Online and offline attracted a total of more than 10,000 viewers.We will jointly explore how to accelerate cutting-edge pharmaceutical research results to benefit patients with chronic diseases and promote global pharmaceutical research and development innovation.
　　Dr Sharon Barr, AstraZeneca Global Executive Vice President, Head of Biopharmaceutical Research and Development, said:"The on-site R & D day provided me with a valuable opportunity to engage in in-depth discussions and explore opportunities for collaboration with experts on a wide range of topics, including chronic diseases, cutting-edge science and emerging biology. In 2023, we reached a number of global agreements with local Chinese innovators and acquired Gen Xi Bio, China's leading cell therapy company. In the future, China will continue to play a key role in the global pharmaceutical industry, bringing more breakthrough therapies and reshaping the life trajectory of global patients."
　　Dr. Seng H. Cheng, AstraZeneca Global Senior Vice President, Head of Rare Disease Drug Research and Product Development, said:"As we move forward with rare disease research, we have noticed that China's potential in emerging areas, including gene therapy and cell therapy, is impressive and could help change the treatment landscape. AstraZeneca China R & D Day is a platform to promote scientific exchanges. Through such a platform, we can have in-depth exchanges with scientists from all over China, explore new opportunities, further advance our research work, and improve the lives of patients with rare diseases."

Focus on cutting-edge scientific achievements and innovative technologies,
Promoting global cooperation in China's innovation ecosystem
 

　　Keynote ForumFocusing on the unfulfilled needs of chronic patients, bringing together a number of AstraZeneca global R & D executives and Chinese experts to discuss the future of pharmaceutical R & D, and discussing and looking forward to innovative therapies including cell therapy and gene therapy, we are confident in further promoting global cooperation in China's innovation ecosystem!

As the highlight of this event,Cell therapy and gene therapyIt is not only frequently mentioned in the keynote forum, but also the focus of the three sub-forums: cell therapy for rare diseases, multi-omics research of Chinese cohort, systemic lupus erythematosus and cell therapy for autoimmune diseases.

▼ Rare Disease Cell Therapy Sub-forum Photo

▼ Photos of the multi-group research sub-forum of the Chinese cohort.

▼ Photos of Cell Therapy for Systemic Lupus Erythematosus and Autoimmune Diseases

　　Hypertension, kidney diseaseThe two sub-forums covered hot topics such as the treatment and management of hypertension, research hotspots of kidney disease and clinical transformation. A number of top experts combined with their own clinical practice experience and the latest research results, together with AstraZeneca scientists to explore the basic research breakthrough of related diseases, the key path of clinical transformation and the cutting-edge treatment progress, and explore the future opportunities for the treatment of related chronic diseases.

▼ Hypertension Sub-forum Photos

▼ Photo of kidney disease sub-forum

This research and development day also focusinfectious diseaseswith high incidence in Chinabronchial diseaseExperts and scholars from all walks of life, including Zhong Nanshan, academician of the Chinese Academy of Engineering, and Gao Fu, academician of the Chinese Academy of Sciences, share their experiences on scientific research progress and clinical transformation from online and on-site, and focus on the unfulfilled needs of patients to jointly promote the development of China and the global pharmaceutical industry and enhance R & D and innovation capabilities, and accelerate the process of new drug research and development.

▼ Infectious diseases sub-forum photos

▼ Photos of non-cystic fibrosis bronchiectasis sub-forum

AstraZeneca has always adhered to the "patient-centered" research and development concept. This research and development day will continue to set up a patient care sub-forum to focus on patients with myasthenia gravis and related rare diseases, and discuss the current disease characteristics, diagnosis and treatment status and the current situation of myasthenia gravis. The challenges are discussed in depth to help pharmaceutical companies listen to the voices of patients and lay a more solid foundation for the future development of rare disease drugs.

▼ Patient Care Sub-Forum

Dr. He Jing, senior vice president of AstraZeneca and head of the global R & D China center, said: "I believe you have fully felt the excitement and expectation of the global R & D management team for China's innovation opportunities and cooperation opportunities in this R & D day. We will continue to use AstraZeneca China R & D Day and multiple channels to further strengthen our R & D capabilities, promote external cooperation, continue to explore opportunities in China, and promote Chinese innovation to the global stage to benefit patients around the world."

Photograph of Dr. Jing He